Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Aytu Biopharma (AYTU) over the last 9 years, with Jun 2025 value amounting to $3.4 million.

  • Aytu Biopharma's Other Accumulated Expenses fell 75.07% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 75.07%. This contributed to the annual value of $3.4 million for FY2025, which is 62.30% down from last year.
  • Aytu Biopharma's Other Accumulated Expenses amounted to $3.4 million in FY2025, which was down 62.30% from $9.0 million recorded in FY2024.
  • Aytu Biopharma's Other Accumulated Expenses' 5-year high stood at $9.0 million during FY2024, with a 5-year trough of $3.4 million in FY2025.
  • For the 3-year period, Aytu Biopharma's Other Accumulated Expenses averaged around $6.5 million, with its median value being $7.1 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 555.70% in 2021, then crashed by 62.30% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's Other Accumulated Expenses stood at $8.3 million in 2021, then slumped by 35.80% to $5.4 million in 2022, then skyrocketed by 32.30% to $7.1 million in 2023, then climbed by 26.40% to $9.0 million in 2024, then crashed by 62.30% to $3.4 million in 2025.